The Effect of Tegoprazan on the Treatment of Endoscopic Resection-Induced Artificial Ulcers: A Multicenter, Randomized, Active-Controlled Study
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Tegoprazan is a novel potassium-competitive acid blocker that has beneficial effects on acid-related disorders such as gastroesophageal reflux and peptic ulcer diseases. This study aimed to validate the effect of tegoprazan on endoscopic submucosal dissection (ESD)-induced artificial ulcers. Methods: Patients from 16 centers in Korea who underwent ESD for gastric neoplasia were enrolled. After ESD, pantoprazole was administered intravenously for 48 hours. The patients were randomly allocated to either the tegoprazan or esomeprazole group. Tegoprazan 50 mg or esomeprazole 40 mg were administered for 4 weeks, after which gastroscopic evaluation was performed. If the artificial ulcer had not healed, the same dose of tegoprazan or esomeprazole was administered for an additional 4 weeks, and a gastroscopic evaluation was performed. Results: One hundred sixty patients were enrolled in this study. The healing rates of artificial ulcers at 4 weeks were 30.3% (23/76) and 22.1% (15/68) in the tegoprazan and esomeprazole groups, respectively (p=0.006). At 8 weeks after ESD, the cumulative ulcer healing rates were 73.7% (56/76) and 77.9% (53/68) in the tegoprazan and esomeprazole groups, respectively (p=0.210). Delayed bleeding occurred in two patients in the tegoprazan group (2.6%) and in one patient in the esomeprazole group (1.5%). Other adverse events were negligible in both groups. Conclusions: Tegoprazan showed similar effects on post-ESD artificial ulcer healing in comparison with esomeprazole.
Abstract
Background/Aims: Tegoprazan is a novel potassium-competitive acid blocker that has beneficial effects on acid-related disorders such as gastroesophageal reflux and peptic ulcer diseases. This study aimed to validate the effect of tegoprazan on endoscopic submucosal dissection (ESD)-induced artificial ulcers. Methods: Patients from 16 centers in Korea who underwent ESD for gastric neoplasia were enrolled. After ESD, pantoprazole was administered intravenously for 48 hours. The patients were randomly allocated to either the tegoprazan or esomeprazole group. Tegoprazan 50 mg or esomeprazole 40 mg were administered for 4 weeks, after which gastroscopic evaluation was performed. If the artificial ulcer had not healed, the same dose of tegoprazan or esomeprazole was administered for an additional 4 weeks, and a gastroscopic evaluation was performed. Results: One hundred sixty patients were enrolled in this study. The healing rates of artificial ulcers at 4 weeks were 30.3% (23/76) and 22.1% (15/68) in the tegoprazan and esomeprazole groups, respectively (p=0.006). At 8 weeks after ESD, the cumulative ulcer healing rates were 73.7% (56/76) and 77.9% (53/68) in the tegoprazan and esomeprazole groups, respectively (p=0.210). Delayed bleeding occurred in two patients in the tegoprazan group (2.6%) and in one patient in the esomeprazole group (1.5%). Other adverse events were negligible in both groups. Conclusions: Tegoprazan showed similar effects on post-ESD artificial ulcer healing in comparison with esomeprazole.
참고문헌 (24)
- Uedo N, "Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer : a prospective randomized controlled trial", Am J Gastroenterol, 102, pp.1610~1616 (2007)
- Ye BD, "Omeprazole may be superior to famotidine in the management of iatrogenic ulcer after endoscopic mucosal resection : a prospective randomized controlled trial", Aliment Pharmacol Ther, 24, pp.837~843 (2006)
- An JY, "The use of endoscopic clipping in preventing delayed complications after endoscopic resection for superficial non-ampullary duodenal tumors", Clin Endosc, 54, pp.563~569 (2021)
- Chey WD, "Treatment patterns and symptom control in patients with GERD : US communitybased survey", Curr Med Res Opin, 25, pp.1869~1878 (2009)
- Jung YS, "Systematic review with metaanalysis : the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication", Aliment Pharmacol Ther, 46, pp.106~114 (2017)
- Miwa H, "Randomised clinical trial : efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers : results from two phase 3, non-inferiority randomised controlled trials", Aliment Pharmacol Ther, 45, pp.240~252 (2017)
- Oshima T, "Randomised clinical trial : vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis", Aliment Pharmacol Ther, 49, pp.140~146 (2019)
- Hamada K, "Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers : a prospective randomized phase II study", J Gastroenterol, 54, pp.122~130 (2019)
- Tsuchiya I, "Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection : prospective randomized controlled trial", Dig Endosc, 29, pp.576~583 (2017)
- Takahashi N, "Tegoprazan, a novel potassiumcompetitive acid blocker to control gastric acid secretion and motility", J Pharmacol Exp Ther, 364, pp.275~286 (2018)
- Cho YK, "Randomised clinical trial : tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer", Aliment Pharmacol Ther, 52, pp.789~797 (2020)
- Choi YJ, "Triple therapy-based on tegoprazan, a new potassium-competitive acid blocker, for first-line treatment of Helicobacter pylori infection : a randomized, double-blind, phase III, clinical trial", Gut Liver, 16, pp.535~546 (2022)
- Lee KJ, "Randomised phase 3 trial : tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis", Aliment Pharmacol Ther, 49, pp.864~872 (2019)
- Kim SH, "Randomised clinical trial : comparison of tegoprazan and placebo in non-erosive reflux disease", Aliment Pharmacol Ther, 54, pp.402~411 (2021)
- Takahashi K, "Vonoprazan 20 mg vs lansoprazole 30 mg for endoscopic submucosal dissectioninduced gastric ulcers", World J Gastrointest Endosc, 8, pp.716~722 (2016)
- Maruoka D, "Vonoprazan is superior to proton pump inhibitors in healing artificial ulcers of the stomach post-endoscopic submucosal dissection : a propensity score-matching analysis", Dig Endosc, 29, pp.57~64 (2017)
- Kang H, "Vonoprazan versus proton pump inhibitors for the management of gastric endoscopic submucosal dissection-induced artificial ulcer : a systematic review with meta-analysis", Medicine(Baltimore), 98, pp.e15860~ (2019)
- Miao T, "Vonoprazan vs. lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer : a systematic review and metaanalysis", Rev Esp Enferm Dig, 115, pp.168~174 (2023)
- Kawai D, "Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection : a randomized, openlabel trial", BMC Gastroenterol, 21, pp.236~ (2021)
- Ishii Y, "Effects of vonoprazan compared with esomeprazole on the healing of artificial postendoscopic submucosal dissection ulcers : a prospective, multicenter, two-arm, randomized controlled trial", Gastroenterol Res Pract, 2018, pp.1615092~ (2018)
- Sakita T, "All about gastric and duodenal ulcer", pp.200~211 (1972), Nankodo
- Choi IJ, "Short-term outcomes of endoscopic submucosal dissection in patients with early gastric cancer : a prospective multicenter cohort study", Gut Liver, 10, pp.739~748 (2016)
- Jenkins H, "Randomised clinical trial : safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438(vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects", Aliment Pharmacol Ther, 41, pp.636~648 (2015)
- He J, "Safety, tolerability and pharmacokinetics of single ascending and multiple oral doses of tegoprazan in healthy Chinese subjects", Clin Drug Investig, 41, pp.89~97 (2021)